MAPT and Alzheimer disease: Studies have shown that by combining various biomarkers, such as amyloid positron emission tomography (PET), fluorodeoxyglucose (FDG)-PET, magnetic resonance imaging (MRI), and cerebral spinal fluid (CSF) measures of amyloid beta (Aβ), total Tau (t-Tau), and phosphorylated Tau (p-Tau), the accuracy for identifying preclinical AD could be improved (Dubois et al., 2014, 2016; Jack et al., 2016, 2018).